

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

BIOCHEMICAL EFFECTS OF ALLOXAN-INDUCED DIABETIC RATS TREATED WITH COMBINED METHANOL EXTRACTS OF *VERNONIA AMYGDALINA* AND *GONGRONEMA LATIFOLIA*

ABSTRACT

Aim: The study investigated effects of combined methanol extracts of *Gongronema latifolium* and *Vernonia amygdalina* on fasting blood glucose (FBG) levels, oxidative stress markers and some haematological indices of alloxan-induced diabetic rats. **Methodology:** Twenty (25) albino wistar rats were assigned into 5 groups of 5 rats per group. Diabetes was induced in groups 2-5 by a single intraperitoneal injection of alloxan monohydrate (160 mg/kg) while group 1 rats served as normal control. Upon establishment of diabetes, group 2 rats were treated with 200 mg/kg of *G. latifolium* extract; group 3 rats with a combination of 100 mg/kg of *G. latifolium* and 100 mg/kg of *V. amygdalina*; group 4 rats with 200 mg/kg of *V. amygdalina* while group 5 rats were treated with 2 mg/kg glibenclamide. All treatments were daily through the oral route for 21 days. The FBG levels of the rats were assessed at 2 h, 6 h and on days 7, 14 and 21 post-treatment while blood for clinical chemistry [Catalase, Superoxide dismutase (SOD) and Malondialdehyde (MDA)] and haematological [Red blood cell (RBC) count, packed cell volume (PCV) and Haemoglobin (Hb) concentration] analyses were collected on day 21. **Results:** Results showed that the FBG level of the rats treated with combined extract decreased significantly ($P < 0.05$) from 203.66 ± 1.85 on day zero to 48.00 ± 3.57 on day 21. The mean catalase activity and MDA levels of the rats that received the combined treatment (group 3 rats) were statistically comparable to that of glibenclamide-treated rats. The SOD activity, RBC count,

24 PCV levels and Hb concentration of the rats in group 3 were significantly ($P < 0.05$) higher than
25 those of the negative control group. **Conclusion:** Treatment of diabetic rats with 100 mg/kg each
26 of methanol extracts of *G. latifolium* and *V. amygdalina* exhibited hypoglycaemic, anti-oxidant
27 and anti-anaemic potentials.

28

29 **Key words:** *Gongronema latifolium* *Vernonia amygdalina* , biochemical, haematology diabetic
30 Rats,

31 INTRODUCTION

32 Diabetes mellitus is derived from the Greek word 'diabetes' meaning siphon (to pass through)
33 and the Latin word 'mellitus' meaning honeyed or sweet. It was known in the 17th century as the
34 'pissing evil' [1]. Diabetes mellitus commonly referred to as diabetes is a group of metabolic
35 diseases in which a person or animal has high blood sugar, either because the pancreas does not
36 produce enough insulin, or because the body's cells do not respond to the insulin that is being
37 produced [2]. This high blood sugar (hyperglycaemia) produces the classical symptoms of
38 polyuria (frequent urination), polydipsia (increased thirst) and polyphagia (increased appetite or
39 hunger).

40 Diabetes was the cause of 4.9 million deaths in 2014 (as against 1.5 million in 2012), implying
41 that every seven seconds, a person died from diabetes. It was also estimated that 1 in 12 people
42 were living with diabetes including diagnosed and undiagnosed cases [3]. In animals, diabetes is
43 most commonly encountered in dogs and cats. Middle-aged animals are most commonly
44 affected. Female dogs are twice as likely to be affected as males while according to some
45 sources, male cats are also more prone than females. In both species, all breeds may be affected

46 but some small dog breeds are particularly likely to develop diabetes such as Miniature Poodles,
47 Dachshunds, Cairn Terriers and Beagles, but any breed can be affected [4]

48 In developing countries, few people have access to the conventional diabetes management
49 drugs, thus, many people use plant for treatment of diabetes. Also, the inadequacies associated
50 with the conventional medicines have led to a determined search for alternative natural
51 therapeutic agents

52 *Vernonia amygdalina* Commonly called bitter leaf is a perennial shrub that belongs to the family
53 *Asteraceae* and grows throughout tropical Africa [5]. Extracts from *V. amygdalina* have been
54 shown to possess anti-diabetic, hepato-protective, serum lipid modulation, and other properties
55 [6]. According to [7] in a study conducted on the effect of *V. amygdalina* extract on blood
56 glucose levels of diabetic rats, there was a remarkable decrease in blood glucose level from mean
57 value 4.44 ± 0.2 to 1.66 ± 0.2 mMol/L. Other researchers [8, 9] have also confirmed
58 hypoglycemic effects of this shrub. *Gongronema latifolium* is a herbaceous, non-woody plant
59 from the family Asclepiadaceae. It produces milky clear latex and is widespread in the tropical
60 and subtropical regions especially in Africa and South America, with a moderate representation
61 in Northern and South Eastern Asia [10]. Pharmacological studies have also shown that *G.*
62 *latifolium* has hypoglycemic properties [11, 12]. In Nigeria, these two plants are used culinarily
63 and there is a dearth of information on some biochemical effects of their combined usage.

64 The available synthetic drugs have complicated mode of intake and they are expensive with
65 serious side effects. There is therefore the need to search for an alternative source of therapy thus
66 this study. This study therefore was to investigate possible haematobiochemical changes that
67 may be associated with the combined usage of these two shrubs on alloxan-induced diabetic rats.

68

69 **MATERIALS AND METHODS**

70 **Materials**

71 **Plant Materials**

72 The leaves of *Gongronema latifolium* (GL) and *Vernonia amygdalina* (VA) were
73 purchased from Ogige market in Nsukka Local Government Area both in Enugu State, Nigeria
74 and were identified by a Botanist in the Botany Department, University of Nigeria, Nsukka.

75 **Chemical, Reagents and Drugs.**

76 Methanol, alloxan monohydrate (SIGMA ALDRICH, U.K.), Red blood cell (RBC) and
77 white blood cell (WBC) diluting fluids and Drabkin's reagent, Malondialdehyde (MDA),
78 superoxide oxide dismutase (SOD) and Catalase reagents Glibenclamide (Hovid[®], Hong Kong)
79 were used

80 **Animals**

81 Male albino Wistar rats weighing between 150-200 g were obtained from the Department
82 of Veterinary Physiology and Pharmacology, University of Nigeria, Nsukka laboratory animal
83 house. The rats were acclimatized for two weeks. The environmental temperature where the
84 animals were housed varied between 28-32 °C. The animals were kept in stainless wire mesh
85 cages and provided with good clean water *ad libitum*. They were fed with Vital feed[®] (grower).

86 **Methods**

87 **Preparation of the Plant Extract**

88 Cold maceration method of extraction was employed. The leaves of *G. latifolium* and *V.*
89 *amygdalina* were air dried at a very low intensity of sunlight to avoid denaturation of the active
90 ingredient. They were pulverized and stored in an air tight container pending its usage. About 2
91 kg of each of the pulverized leaves were soaked separately in 10 liters of 80 % methanol with
92 intermittent shaking every 2 hours for 48 hours. The mixtures were filtered using Whatmann No
93 1 filter paper. The filtrates were concentrated using rotary evaporator and the extract stored at 4
94 °C.

95 **Experimental Design**

96 Twenty five (25) adult male albino wistar rats weighing between 150-200 g were
97 assigned to 5 groups of 5 rats per group. Diabetes was induced in rats of groups 2-5 while group
98 1 rats served as normal control. Upon establishment of diabetes, (Rats with fasting blood glucose
99 values above 7 mmol/L (126 mg/dl) were considered diabetic.), the rats were treated as shown
100 below:

GROUPS	TREATMENT
1	NORMAL CONTROL + 10 ml/kg Distilled water
2	DIABETIC + 200 mg/kg GL
3	DIABETIC + 100 mg/kg GL and 100 mg/kg VA
4	DIABETIC + 200 mg/kg VA
5	DIABETIC + 2 mg/kg Glibenclamide

101

102 The treatment was through the oral route daily for 21 days. The FBG levels were assessed
103 2 h, 6 h, 7 days, 14 days and 21 days post treatment. On the 21st day, blood samples were

104 collected into EDTA bottles for haematological (red blood cell, white blood cell, packed cell
105 volume, and haemoglobin concentration) analyses while plasma was used for biochemical
106 (superoxide dismutase, catalase and malondialdehyde) determinations.

107 **Induction of Experimental Diabetes mellitus**

108 Diabetes was induced in rats using the method described by [13]. The rats were fasted for 16
109 h prior to induction of diabetes. Diabetes was induced by single intraperitoneal injection of
110 alloxan monohydrate at the dose of 160 mg/kg. Diabetes was established on day two post
111 induction on confirmation of fasting blood glucose levels above 7 mmol/l or 126 mg/dl

112

113 **Estimation of Superoxide dismutase**

114 Superoxide dismutase activity was assayed by the method of [14]. 0.5 ml of plasma
115 was diluted to 1.0 ml with ice cold water, followed by 2.5 ml ethanol and 1.5 ml
116 chloroform (chilled reagent). The mixture was shaken for 60 seconds at 4°C and
117 then centrifuged. The enzyme activity in the supernatant was determined as
118 follows. The assay mixture contained 1.2 ml of sodium pyrophosphate buffer, 0.1
119 ml of PMS and 0.3 ml of NBT and approximately diluted enzyme preparation in a
120 total volume of 3 ml. The reaction was started by
121 the addition of 0.2 ml NADH. After incubation at 30°C for 90 seconds, the
122 reaction was stopped by the addition of 1 ml glacial acetic acid. The reaction
123 mixture was stirred vigorously and shaken with 4 ml n-butanol. The mixture was
124 allowed to stand for 10 minutes, centrifuged and butanol layer was separated. The
125 colour intensity of the chromogen in the butanol layer was measured in a
126 spectrophotometer at 520 nm. A system devoid of enzyme served as control. One
127 unit of enzyme activity is defined as the enzyme concentration, which gives 50%

128 inhibition of NBT reduction in one minute under assay conditions. SOD activity
129 was expressed as U/ml of plasma.

130

131 **Estimation of Catalase**

132 The activity of catalase was assayed by the method of [15]. To 0.9 ml of phosphate,
133 0.1 ml of plasma and 0.4 ml of H₂O₂ added. The reaction was stopped after 15, 30,
134 45 and 60 seconds by adding 2 ml of dichromate acetic acid mixture. The tubes
135 were kept in a boiling water bath for 10 minutes, cooled and the colour developed
136 was read at 530 nm. Standards in the concentration range of 20-100 μmoles was
137 processed for the test. The activity of catalase was expressed as U/ml for plasma
138 (U- μmoles of H₂O₂ Utilised / second).

139

140 **Estimation of Lipid Peroxidation (Malondialdehyde)**

141 Lipid peroxidation was estimated by measuring spectrophotometrically, the level of the
142 lipid peroxidation product, malondialdehyde (MDA) as described by [16]. A volume, 0.1ml
143 of the serum was mixed with 0.9ml of H₂O in a test tube. A volume, 0.5ml of 25%
144 TCA (trichloroacetic acid) and 0.5ml of 1% TBA (thiobarbituric acid) in 0.3%
145 NaOH were also added to the mixture. The mixture was boiled for 40 minutes in
146 water-bath and then cooled in cold water. Then 0.1ml of 20% sodium dodecyl
147 sulfate (SDS) was added to the cooled solution and mixed properly. The
148 absorbance was taken at wavelength 532nm and 600 nm against a blank.

149 $\% \text{ TBARS} = \frac{A_{532} - A_{600} \times 100}{0.5271 \times 0.1} \quad (\text{mg/dl})$

150 0.5271×0.1

151

152

153 **Blood Collection for Haematological Analyses**

154 Blood samples were collected from the rats using orbital technique, that is, from the
155 retrobulbar plexus of the median canthus of the eye. Plasma for *in vivo* antioxidant assay was
156 obtained by centrifuging the EDTA-treated blood sample and decanting the supernatant into
157 another clean sample bottle.

158 **Determination of Packed Cell Volume**

159 The packed cell volume (PCV) was determined by the microhaematocrit method [17].
160 Micro-capillary tubes were almost filled with the anti-coagulated blood samples and one end
161 sealed with plasticine. The filled tubes were centrifuged at 10,000 revolutions per minute for 5
162 minutes using a microhaematocrit centrifuge (Hawksley, England). The PCV was read as a
163 percentage on the microhaematocrit reader

164 **Determination of Haemoglobin Concentration**

165 The haemoglobin concentration (Hb) was determined by the cyanomethaemoglobin
166 method [18]. The blood sample (0.02 ml) was added to 5 ml of Drabkins reagent in a clean test
167 tube. This was mixed gently and kept at room temperature for 20 minutes to react. The
168 absorbances of both sample and standard were read, against a working reagent blank at a
169 wavelength of 540 nm using a spectrophotometer (Lab-tech, India). The haemoglobin
170 concentration of the blood sample was obtained by multiplying the absorbance of the sample
171 with the factor derived from the absorbance and concentration of the standard

172 **Erythrocyte Count**

173 The erythrocyte count was determined by the haemocytometer method [17]. Blood
174 sample (0.02 ml) was added to 4 ml of red blood cell diluting fluid (sodium citrate, formaldehyde
175 solution and distilled water) in a clean test tube, to make a 1:200 dilution. A drop of the diluted

176 blood was charged onto the Neubauer counting chamber and allowed to settle for 2-3 minutes.
177 The objective (x 40) lens of the light microscope was used in carrying out the erythrocyte count,
178 in the five groups of 16 small squares. The number of erythrocytes enumerated for each sample
179 was multiplied by 10,000 to obtain the erythrocyte count per microlitre of blood

180 **Total Leukocyte Count**

181 The total leukocyte count was determined by the haemocytometer method [17]. Blood
182 sample (0.02 ml) of blood was added to 0.38ml of white blood cell diluting fluid (glacial acetic
183 acid tinged with gentian violet) in a clean test tube, to make a 1:20 dilution. A drop of the diluted
184 blood was charged onto the Neubauer chamber and allowed to settle for 2 minutes. The x10
185 objective lens of the light microscope was used in making a total count of white blood cells on
186 the four corner squares. The number of cells counted for each blood sample was multiplied by 50
187 to obtain the total leukocyte count per microlitre of blood

188 **STATISTICAL ANALYSIS**

189 Data obtained from the study were analyzed using One-way Analysis of Variance (ANOVA).
190 Duncans Multiple Range post hoc test was used to separate variant means. P (probability) values
191 less than 0.05 were considered significant. The results were presented as mean \pm Standard Error
192 of the Mean (SEM).

193 **RESULTS**

194 **Table 1: Effect of the Methanol Extract of *V. amydalina* and *G. latifolium* on the Fasting** 195 **Blood Glucose (FBG) Levels of Alloxan-induced Diabetic Rats**

196 The pre-induction fasting blood glucose (FBG) levels of the rats in groups 1-5 were
197 statistically comparable ($P > 0.05$). However, the post-induction FBG of the rats in groups 2-5
198 increased significantly ($P < 0.05$) compared to the FBG of group 1 rats (normal control).

199 Two hours (2 h) post-treatment, the FBG of groups 3-5 rats were statistically comparable
200 ($P > 0.05$) but were significantly ($P < 0.05$) lower than that of the group 2 rats. The FBG of the
201 group 1 rats were equally comparable ($P > 0.05$) to that of the group 5 rats.

202 On the 6th hour post treatment, the FBG levels of the rats in groups 3-5 were statistically
203 comparable ($P > 0.05$) but were still significantly ($P < 0.05$) higher than those of the group 1 rats
204 (normal control) and significantly ($P < 0.05$) lower than those of the group 2 rats.

205 The FBG levels of the rats in groups 2-5 were statistically comparable ($P > 0.05$) but
206 were significantly ($P < 0.05$) higher than those of the group 1 rats on the 7th day post-treatment.

207 On day 14 post-treatment however, the FBG levels of the rats in groups 1 & 3 were
208 statistically comparable ($P > 0.05$) but were significantly ($P < 0.05$) higher than that of the group
209 5 rats. Rats in group 2 and 4 had FBG levels that were comparable ($P > 0.05$) to each other but
210 were statistically higher than that of the other groups.

211 On the 21st day post-treatment, the rats in group 3 had a significantly ($P < 0.05$) lower
212 FBG level compared to other groups, the FBG levels of the rats in group 1 & 5 were statistically
213 comparable ($P > 0.05$), while the FBG levels of the rats in group 2 were significantly ($P < 0.05$)
214 higher than those of the rats in the other groups.

215 **Table 2: Effect of the Methanol Extract of *Vernonia amygdalina* and *Gongronema latifolium***
216 **on Oxidative Stress Markers of Alloxan-Induced Diabetic Rats**

217

218 The table indicates that the catalase activities of the rats in groups 2-5 were statistically
219 comparable ($P > 0.05$) but were significantly ($P < 0.05$) lower than that of the group 1 rats.

220 The SOD activities of group 4 rats compared favorably with those of the other groups.
221 However, the SOD activities of the rats in groups 1, 2 & 5 were significantly ($P < 0.05$) lower
222 than those of the other groups while the SOD activities of the rats in group 3 were significantly
223 ($P < 0.05$) higher than those of the other groups.

224 The MDA levels of the rats in group 5 were significantly ($P < 0.05$) lower than those of
225 the other groups while those of the rats in group 2 were significantly ($P < 0.05$) higher than those
226 of the other groups. However, the MDA levels of the rats in groups 1, 3 & 4 compared favorably
227 with those of groups 2 & 5.

228

229 **Table 3: Effect of the Methanol Extract of Vernonia amygdalina and Gongronema**
230 **latifolium on Some Haematological Indices of Alloxanized Rats**

231 The red blood cell (RBC) count of the rats in groups 1, 3 & 5 were statistically
232 comparable ($P > 0.05$) while those of the rats in group 2 were significantly ($P < 0.05$) lower than
233 those of the other groups. The RBC count of the rats in group 4 were significantly ($P < 0.05$)
234 higher than those of the rats in group 2 but were lower than those of groups 1 & 3.

235 The packed cell volume (PCV) levels of the rats in group 3 compared favorably with
236 those of the rats in the other groups. The PCV levels of the rats in group 1 was significantly ($P <$
237 0.05) higher than those of the other groups but was statistically comparable to ($P > 0.05$) those of
238 group 3.

239 The haemoglobin (Hb) levels of the rats in groups 2-5 were statistically comparable ($P >$
240 0.05). The Hb levels of group 1 rats compared very well with those of group 5 rats but was
241 significantly ($P < 0.05$) higher than those of the rats in groups 2-4.

242 The white blood cell counts of the rats in all the groups (groups 1-5) were
243 statistically comparable ($P > 0.05$) to each other.

244 **DISCUSSION**

245 Upon the administration of alloxan monohydrate to the rats in the treatment groups
246 (groups 2-5), there was a significant ($P < 0.05$) increase in FBG levels of the rats to levels
247 positive for diabetes mellitus (DM) as against the normal controls. This was attributed to the
248 effect of alloxan monohydrate. Alloxan monohydrate is a toxic glucose analogue which
249 selectively destroys the insulin-producing β cells in the pancreas when administered to rodents
250 and many other animal species [19]. There was a significant ($P < 0.05$) reduction in the FBG of
251 rats treated with *Gongronema latifolium* (GL) extract from the 1st to the 21st day of treatment by
252 51.7%. Francis *et al.*, [12] had earlier reported hypoglycaemic potentials of *G. latifolium*. The
253 effect was thought to be mediated through the activation of hexokinase, phosphofructokinase,
254 glucose-6-phosphatase dehydrogenase and the inhibition of glucose kinase in the liver [11]

255 Similarly, there was a significant ($P < 0.05$) reduction in the FBG of rats treated with
256 *Vernonia amygdalina* (VA) extract. The percentage reduction from the initial hyperglycaemic
257 level was 55%. The anti-hyperglycaemic effect of VA has been reported by other researchers [8,
258 9]. The work of [20] suggests that VA may exert anti-diabetic or glucose-lowering action by a
259 simultaneous suppression of gluconeogenesis and potentiation of glucose oxidation via the
260 pentose phosphate pathway almost exclusively in the liver.

261 The decrease in FBG resulting from the treatment with glibenclamide (77.3 %) was
262 comparable to the decrease brought about by the treatment with the combination of VA and
263 GL extracts (76.7 %). This striking hypoglycaemic activity achieved by combining VA and GL

264 could be because the phytochemical components of the different plants worked synergistically to
265 bring about a significant ($P < 0.05$) decrease superior to either of the plants used alone.

266 Superoxide dismutase (SOD) is an enzyme that catalyzes the dismutation (or partitioning)
267 of superoxide (O_2^-) radical into either ordinary molecular oxygen or hydrogen peroxide.
268 Superoxide is produced as a byproduct of oxygen metabolism and if not regulated, causes many
269 types of cell damage. Hydrogen peroxide is also damaging but less so and is degraded by other
270 enzymes such as catalase. Thus, SOD is an important antioxidant defense in nearly all living
271 cells exposed to oxygen [21]. The study showed that rats in the group treated with a combination
272 of GL and VA had a significantly ($P < 0.05$) higher SOD activity compared to the other groups.
273 A synergy in the phytochemical components of both extracts is probably responsible for this.

274 Catalase is a common enzyme found in nearly all living organisms exposed to oxygen
275 (such as bacteria, plants and animals). It catalyzes the decomposition of hydrogen peroxide to
276 water and oxygen [22]. It is a very important enzyme in protecting the cell from oxidative
277 damage by reactive oxygen species (ROS). Catalase is frequently used by cells to rapidly
278 catalyze the decomposition of hydrogen peroxide to less-reactive gaseous oxygen and water
279 molecules [23]. It has been reported that a catalase deficiency may increase the likelihood of
280 developing type 2 diabetes mellitus [24]. Studies have also shown that patients with diabetes
281 mellitus usually have a reduced catalase activity [25]. Rats that received the combined treatment
282 of GL and VA produced a higher catalase activity than the other treatment groups.

283 The Malondialdehyde levels of the rats treated with a combination of the extracts was
284 however lower than those of the rats treated with either of the extracts signifying a less lipid
285 peroxidative activity in this group of rats. Malondialdehyde (MDA) is the organic compound that

286 results from the lipid peroxidation of poly unsaturated fatty acids [26] and it is therefore a marker
287 of oxidative stress [27]. This compound is a reactive aldehyde and is one of the many reactive
288 electrophile species that cause toxic stress in cells and form covalent protein adducts [28]

289 Anaemia is a common finding in patients with diabetes mellitus particularly in those with
290 overt nephropathy[29]. Similarly, another study showed that the mean values of red blood cell
291 (RBC) count, haemoglobin (Hb) concentration, packed cell volume (PCV) and mean corpuscular
292 haemoglobin concentration (MCHC) for the diabetic patients were lower than the values of the
293 control group indicating the presence of anaemia in the former group [30]. Previous report
294 indicates that the occurrence of anaemia in DM is due to increased non-enzymatic glycosylation
295 of RBC membrane proteins which correlates with hyperglycaemia [31]. On the other hand,
296 research has shown that WBC counts are significantly higher among diabetics compared to non-
297 diabetics and that there is a positive correlation between raised WBC levels and poor glycaemic
298 control defined as hyperglycaemia [32]

299 The result of this study as seen in table 3 shows that rats treated with a combination of
300 GL and VA leaf extracts had RBC counts ($6.44 \pm 0.32 \times 10^6$ millions/ μ l) statistically comparable
301 to those of the normal control ($6.92 \pm 0.2 \times 10^6$ millions/ μ l). The RBC counts of the rats that
302 received the combined treatment was significantly ($P < 0.05$) higher than those of the rats that
303 received either of the extracts alone signifying a better glycaemic control as explained by
304 Thomas and Rampersad, (2004).

305 The PCV of the rats in the treatment groups were statistically comparable but were
306 significantly lower than those of the normal control. The rats that received the combined
307 treatment however had PCV levels (38.66 ± 0.33 %) similar to those of the normal control (40.33

308 ± 0.33 %). This also indicates a better glycaemic control exerted by the combination of the
 309 extracts.

310 The study also shows that the WBC count of all the rats in the different groups
 311 were statistically comparable although those of the rats that received the combined treatment
 312 ($6.87 \pm 0.03 \times 10^3$ thousand/ μ l) was closest to those of the normal controls ($6.89 \pm 0.01 \times 10^3$
 313 thousand/ μ l).

314 CONCLUSION

315 The results of the present study show that the combination of the methanol extracts of GL
 316 and VA exhibited hypoglycaemic, *in vivo* anti-oxidant effects in addition to a positive effect on
 317 haematological indices superior to either of the extracts used alone.

318 **Table 1: Effect of the Methanol Extract of *V. amydalina* and *G. latifolium* on the Fasting**
 319 **Blood Glucose (FBG) Levels of Alloxan-induced Diabetic Rats.**

Group	Pre- induction FBG (mg/dl)	Post- induction FBG (mg/dl)	2 h post- treatment FBG (mg/dl)	6 h post- treatment FBG (mg/dl)	7days post- treatment FBG (mg/dl)	14days post- treatment FBG (mg/dl)	21days post- treatment FBG (mg/dl)
1	78.66 \pm 0.33 ^a	75.00 \pm 1.15 ^a	77.66 \pm 0.88 ^a	69.00 \pm 0.57 ^a	75.33 \pm 0.88 ^a	77.33 \pm 4.48 ^b	70.66 \pm 1.76 ^b

2	78.00 ± 2.08 ^a	209.33 ± 0.88 ^c	185.33 ± 7.53 ^c	157.66 ± 21.78 ^c	105.00 ± 2.88 ^b	104.33 ± 2.84 ^c	101.00 ± 2.08 ^d
3	78.33 ± 0.88 ^a	203.66 ± 1.85 ^b	135.00 ± 18.17 ^b	102.00 ± 1.15 ^b	93.66 ± 4.84 ^b	68.00 ± 6.80 ^b	48.00 ± 3.57 ^a
4	77.66 ± 4.91 ^a	204.33 ± 1.76 ^b	116.00 ± 7.02 ^b	120.66 ± 5.36 ^b	106.33 ± 8.76 ^b	93.66 ± 2.40 ^c	91.66 ± 2.72 ^c
5	78.66 ± 1.52 ^a	210.00 ± 0.58 ^c	105.55 ± 3.46 ^{ab}	102.33 ± 1.20 ^b	102.33 ± 0.88 ^b	53.00 ± 1.00 ^a	71.60 ± 6.00 ^b

320 a, b, c and d indicate significant difference at P<0.05 down the groups (down the column).

321 **Table 2:Effect of the Methanol Extract of *Vernonia amygdalina* and *Gongronema latifolium***
 322 **on Oxidative Stress Markers of Alloxan-Induced Diabetic Rats.**

Group	Catalase (U/ml)	SOD (U/ml)	MDA (g/dl)
1	5.00 ± 0.10 ^b	0.57 ± 0.03 ^a	4.39 ± 0.04 ^{ab}

2	2.73 ± 0.25 ^a	0.58 ± 0.05 ^a	5.88 ± 0.86 ^b
3	2.98 ± 0.26 ^a	0.74 ± 0.02 ^b	4.55 ± 0.25 ^{ab}
4	2.42 ± 0.62 ^a	0.64 ± 0.04 ^{ab}	5.45 ± 0.33 ^{ab}
5	3.18 ± 0.16 ^a	0.51 ± 0.04 ^a	4.18 ± 0.455 ^a

323

324 a and b indicate significant difference at $P < 0.05$ down the columns (across the
325 groups).

326

327 SOD- Superoxide Dismutase

328 MDA- Malondialdehyde

329 **Table 3: Effect of the Methanol Extract of Vernonia amygdalina and Gongronema**
 330 **latifolium on Some Haematological Indices of Alloxanized Rats.**

Group	RBC count(x10⁶) (millions/μl)	PCV (%)	Hb Conc. (g/dl)	WBC count(x10³) (thousands/μl)
1	6.92 \pm 0.20 ^c	40.33 \pm 0.33 ^b	13.66 \pm 0.33 ^b	6.89 \pm 0.01 ^a
2	4.85 \pm 0.47 ^a	37.00 \pm 0.577 ^a	12.66 \pm 0.16 ^a	6.66 \pm 0.33 ^a
3	6.44 \pm 0.32 ^c	38.66 \pm 0.33 ^{ab}	12.83 \pm 0.16 ^a	6.87 \pm 0.03 ^a
4	5.64 \pm 0.16 ^b	37.66 \pm 0.33 ^a	12.66 \pm 0.33 ^a	6.64 \pm 0.22 ^a
5	6.18 \pm 0.18 ^{bc}	38.40 \pm 0.36 ^a	13.16 \pm 0.16 ^{ab}	6.61 \pm 0.31 ^a

331 a, b and c indicate significant difference at $P \leq 0.05$ down the columns.

332 RBC count- Red blood cell count

333 PCV- Packed cell volume

334 Hb- Haemoglobin

335 **ETHICAL APPROVAL**

336

337 All authors hereby declare that “principles of laboratory animal care” (NIH publication No 85-
338 23, revised 1985) were followed, as well as specific national laws. All experiments have been
339 examined and approved by the appropriate ethics committee

340

341 **REFERENCES**

- 342 1. Ahmed , AM (2002) “History of Diabetes Mellitus” *Saudi Med J*; 23 (4): 373-8.
- 343 2. Twari, AK; Rao JM (2002) “Diabetes Mellitus and Multiple Therapeutic Approaches of
344 Phytochemicals: Present Status and Future Prospects”, *Current Science*; 83: 30-37.
- 345 3. International Diabetes Federation Diabetes Atlas, “Diabetes Facts and Figures” 6th edn
346 update, 2014.
- 347 4. Kahn, C (2005) ‘The Merck Veterinary Manual’, Merck and co. Inc. Whitehouse station,
348 NJ., USA.
- 349 5. Erasto, P; Grierson, DS; Afolayan, AJ (2006) “Bioactive Sesquiterpene Lactones from
350 the Leaves of *Vernonia amygdalina*” *Nutr Food Sci*; 38: 99-109
- 351 6. Ijeh, II; Ejike, CECC (2011) “Current Perspectives on the Medicinal Potential of
352 *Vernonia amygdalina* Del” *j. Med. Plant Res.* 5(7)”1051-1061

- 353 7. Nwaoguikpe, RN (2010) “The Effect of Extract of Bitter Leaf (*Vernonia amygdalina*) on
354 Blood Glucose Levels of Diabetic Rats” *International Journal of Biological and*
355 *Chemical Sciences*; Vol. 4(3). ISSN 1991-8631
- 356 8. Osinubi, AAA (2007) “Effects of *Vernonia amygdalina* and Chlorpropamide on Blood
357 Glucose” *Med. J. Islam. World Acad. Sci.* 16: 115-11
- 358 9. Fasola, TR; Okeocha, PC; Odetola, A (2010) “Screening for the Hypoglycaemic
359 Potentials of the Extract of *Vernonia amygdalina*” *Ethnobotanical Leaflets* vol. 14: 759-
360 765.
- 361 10. Agbo, CU; Baiyeri, KP; Obi, IU (2005) “Indigenous Knowledge and Utilization of
362 *Gongronema latifolium* Benth: A Case Study of Women in University of Nigeria
363 Nsukka” *Bio-Research Journal*, Vol. 3(2) 66-69.
- 364 11. Ugochukwu, NH; Babady, NE (2003) “Antihyperglycaemic Effect of Aqueous and
365 Ethanolic Extracts of *Gongronema latifolium* leaves on Glucose and Glycogen
366 Metabolism in livers of Normal and Streptozotocin-induced Diabetic Rats” *Life Sciences*,
367 Vol. 73(5): 1925-1938.
- 368 12. Francis V. Udoh; Grace A. Eshiet; Joneas O. Akpan (Late); Frank E. Edu (Late) (2013)
369 “Hypoglycaemic Effect of *Gongronema latifolium* Extracts in Rats” *Journal of Natural*
370 *Sciences Research* Vol. 3(5). ISSN 2224-3186 (Paper) ISSN 225-0921 (Online).
- 371 13. Venogopal, PM; Prince, PSM; Pari, L. (1998) “Hypoglycemic Activities of *Syzigium*
372 *cumini* seeds Effect on Lipid Peroxidation in Alloxan Diabetic Rats.” *Journal of*
373 *Ethnopharmacology* 61: 1-7
- 374 14. Kakkar, SB; Viswanaathan, P (1989) “A Modified Spectrophotometric Assay of
375 Superoxide dismutase” *Indian J. Biochem. Biophysics*, 21: 130-132.

- 376 15. Sinha, AK (1972) "Colorimetric Assay of Catalase" *Anal. Biochem.* 47 (2): 389-92
- 377 16. Wallin, B; Rosengren, B; Shertzer, HG; Camejo, G (1993) "Lipoprotein Oxidation and
378 Measurement of TBARS Formation in a Single Microliter Plate; its use for Evaluation of
379 Antioxidants". *Anal. Biochem.* 208:10-15
- 380 17. Thrall, MA; Weiser, MG (2002) "Haematology" Pp 29-74 In: Hendrix, CM (Ed.),
381 "Laboratory Procedures for Veterinary Technicians" 4th Edn, Mosby Incorporated,
382 Missouri, USA.
- 383 18. Higgins, T; Beutler, E; Doumas, BT; (2008) "Measurement of Haemoglobin in Blood" in
384 Burtis, CA; Ashwood, ER; Bruns, DE (Eds.), *Tietz Fundamentals of Clinical Chemistry*,
385 6th Edition, Saunders Elsevier, Missouri. Pp 514-515.
- 386 19. Lenzen, S (2008) "The Mechanisms of Alloxan and Streptozotocin-Induced Diabetes"
387 *Diabetologia*; 51(2): 216-226. doi: 10.1007/s00125-0070886-7. PMID 18087688
- 388 20. Atangwho, Item Justin; Khoo Boon Yin, Muhammad Ihtisham Umar, Mariam Ahmad
389 and Mohd Zaini Asmawi (2014) "*Vernonia amygdalina* Simultaneously Suppresses
390 Glucose Oxidation via the Pentose Phosphate Pathway in Streptozotocin-Induced
391 Diabetic Rats" *BMC Complementary Altern Med.* 14:426
- 392 21. Borgstahl, GE; Parge, HE; Hickey, MJ; Johnson, MJ; Boissinot, M; Hallewell, RA,
393 Leprock, JR; Cabelli, De; Tainer, JA (1996) "Human Mitochondrial Manganese
394 Superoxide Dismutase Polymorphic Variant ile58Thr Reduces Activity by Destabilizing
395 the tetrameric Interfere". *Biochemistry* 35(14): 4287-97. doi: 10.1021/bi951892w. PMID
396 8605177

- 397 22. Chelikani, P; Fita, L; Loewen, PC (2004) "Diversity of Structures and Properties Among
398 Catalases" *Cell Mol. Life Sci.* 61(2): 192-208. doi: 10.1007/s00018-003-3206-5. PMID
399 14745498.
- 400 23. Gaetani, GF; Ferraris, AM; Rolfo, M; Managerini, R; Arena, S; Kirkman, HN (1996)
401 "Predominant Role of Catalase in the Disposal of Hydrogen Peroxide within Human
402 Erythrocytes" *Blood*; 87(4): 1595-9 PMID 8608252.
- 403 24. Goth, L (2008) "*Catalase Deficiency and Type 2 Diabetes*" *Diabetes Care* 24(10): e93-
404 e93. doi: 10.2337/dc08-1607. PMID 19033415
- 405 25. Cojocar, IM; Cojocar, M; Musuroi, C; Botezat, M; Lazar, L; Druta, A (2004) "Lipid
406 Peroxidation and Catalase in Diabetes mellitus With and Without Ischemic Stroke" *Rom*
407 *J Intern Med.* 42(2) : 423-9. PMID 15529632
- 408 26. Davey, MWI; Stals, E; Panis, B; Keulemans, J; Swennen, RL (2005) "High-throughput
409 Determination of Malondialdehyde in Plant Tissues" *Analytical Biochemistry* 347 (2):
410 201-207. doi: 10.1016/j.ab.2005.09.041. PMID 16289006
- 411 27. Del Rio, D; Stewart, AJ; Pellegrini, N (2005) "A Review of Recent Studies on
412 Malondialdehyde as Toxic Molecule and Biological Marker of Oxidative Stress" *Nutr*
413 *Metab Cardiovasc Dis.* 15(4): 316-28. Doi: 10.1016/j.numed.2005.05.003. PMID
414 16054557
- 415 28. Farmer, EE; Davoine, C (2007) "Reactive Electrophile Species" *Curr. Opin. Plant Biol.*
416 10(4): 380-6. doi: 10.1016/j.pbi.2007.04.019. PMID 17646124
- 417 29. Oyedemi, SO; Yakubu, MT; Afolayan, AJ (2011) "Antidiabetic Activities of Aqueous
418 Leaves Extract of *Leonotis leonurus* in Streptozotocin Induced Diabetic Rats" *J Med*
419 *Plant Res.* 5: 119-125.

420 30. Ruchi, Kothari; Pradeep, Bokariya (2012) “A Comparative Study of Haematological
421 Parameters in Type 1 Diabetes Mellitus Patients and Healthy Young Adolescents” *Int J*
422 *Biol Med Res.* 3:2429-2432

423

424 31. Thomas, S; Rampersad, M (2004) “Anaemia in Diabetes” *Acta Diabetol.* 41 Suppl 1: 13-
425 17.

426 32. Uko, EK; Erhabor, O; Isaac, IZ; Abdulrahaman, Y; Adias, TC *et. al.* (2013) “Some
427 Haematological Parameters in Patients with Type 1 Diabetes in Sokoto, North Western
428 Nigeria” *J. Blood Lymph* 3(1): 110. Doi: 10.4172/2165-7831.1000110. ISSN: 2165-7831

429